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Abstract
Dietary long-chain n-3 PUFA (n-3 LCPUFA) in infancy may have long-term effects on lifestyle disease risk. The present follow-up study
investigated whether maternal fish oil (FO) supplementation during lactation affected growth and blood pressure in adolescents and whether
the effects differed between boys and girls. Mother–infant pairs (n 103) completed a randomised controlled trial with FO (1·5 g/d n-3 LCPUFA)
or olive oil (OO) supplements during the first 4 months of lactation; forty-seven mother–infant pairs with high fish intake were followed-up for
4 months as the reference group. We also followed-up 100 children with assessment of growth, blood pressure, diet by FFQ and physical
activity by 7-d accelerometry at 13·5 (SD 0·4) years of age. Dried whole-blood fatty acid composition was analysed in a subgroup (n 49).
At 13 years of age, whole-blood n-3 LCPUFA, diet, physical activity and body composition did not differ between the three groups.
The children from the FO group were 3·4 (95% CI 0·2, 6·6) cm shorter (P= 0·035) than those from the OO group, and tended to have less
advanced puberty (P= 0·068), which explained the difference in height. There was a sex-specific effect on diastolic blood pressure
(Psex× group= 0·020), which was driven by a 3·9 (95% CI 0·2, 7·5)mmHg higher diastolic blood pressure in the FO compared with the
OO group among boys only (P= 0·041). Our results indicate that early n-3 LCPUFA intake may reduce height in early adolescence due to a
delay in pubertal maturation and increase blood pressure specifically in boys, thereby tending to counteract existing sex differences.
Key words: n-3 Long-chain PUFA: Puberty: Growth: Programming: Health
Dietary long-chain n-3 PUFA (n-3 LCPUFA) are required for
normal child development(1), and intake of n-3 LCPUFA during
early infancy has also been proposed to have long-term effects
on IQ and cardiovascular health(1,2). During infancy, breast milk
is an important source of n-3 LCPUFA, specifically DHA(1,3),
and breast-feeding compared with formula feeding has been
associated with long-term favourable effects on BMI(4) and
blood pressure(5,6). These effects could in part be due to the
relatively high content of DHA in breast milk, as infant formula
until recently did not contain LCPUFA. However, a few studies
have investigated the potential effects of early n-3 LCPUFA
supplementation on later health.
Animal studies have shown that n-3 LCPUFA can act as a
nutritional programming factor in prenatal and postnatal life,
affecting the proliferation and differentiation of pre-adipocytes and
preventing excessive adipose tissue development(7,8). The few
studies that have examined the effects of early n-3 LCPUFA supply
through infant formula or breast milk on children’s body
composition later in life show conflicting results(9–12). Furthermore,
it is difficult to interpret whether the observed effects are indeed
beneficial as body composition varies with decreasing BMI from
about 1 year of age and then rebounds at 4–7 years of age from
where it increases towards adult levels(13). Thus, some of the
inconsistency could be due to fluctuations in body composition
during growth. Pedersen et al.(14) observed that high DHA
concentration in breast milk was associated with a delay in the
timing of adiposity rebound, most strongly in girls, which could
be protective against later obesity. It may therefore be relevant to
assess potential effects later in childhood.
In rodents, perinatal intake of n-3 PUFA has been shown to
reduce blood pressure later in life(15,16). Human intervention
studies have also indicated that early intake of n-3 LCPUFA can
affect later blood pressure, but the results are inconsistent. One
study found that addition of LCPUFA to infant formula was
associated with a lower mean arterial blood pressure (MAP) and
diastolic blood pressure (DBP) at 6 years of age(17). In contrast, no
Abbreviations: DBP, diastolic blood pressure; FO, fish oil; n-3 LCPUFA, long-chain n-3 PUFA; MAP, mean arterial blood pressure; OO, olive oil.
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difference in blood pressure at 8 years of age was found in a
randomised controlled trial where children received fish oil (FO)
supplements from the time they stopped breast-feeding to
age 5 years(18). Another follow-up study showed no difference in
blood pressure among the 19-year-old offspring of mothers who
were randomly allocated to either n-3 LCPUFA supplementation
or control during the last trimester of pregnancy(19). In our FO
supplementation trial during lactation(20), we found higher
blood pressure at 7 years of age in sons of mothers who were
supplemented with FO, but no effect among girls(10). In another
previous study, we have also observed sex-specific effects of n-3
LCPUFA supplementation on blood pressure in children(21) and
sex-specific associations between n-3 LCPUFA status and blood
pressure(22,23). Sex differences in response to n-3 LCPUFA intake
during infancy have also been observed by others with respect to
cognitive outcomes(24), but have not been taken into account in
most studies with focus on growth or in studies with long-term
follow-up.
Therefore, the aim of the present follow-up study was to explore
the effect of maternal FO supplementation during lactation on
growth, body composition and blood pressure in the offspring at
13 years of age, in order to investigate whether the previous
observed associations were transient or withstanding. We further-
more aimed to examine potential effect modifications by sex.
Methods
Study design, participants and intervention
The present 13-year follow-up study was based on a double-
blinded randomised controlled trial in lactating mothers(20).
We conducted three previous follow-up studies among the
offspring – at age 9 months(20), 2·5 years(25) and 7 years(10). The
original trial and the previous and present follow-up studies
are registered at ClinicalTrials.gov (NCT00266305), approved by
the Committees on Biomedical Research Ethics for the Capital
Region of Denmark (KF 01-300/98, KF 01-183/01, KF 11321572
and H-3-2012-150), and all custody holders of each child gave
informed written consent for participation.
The original trial recruited healthy, Danish pregnant women
from the Danish National Birth Cohort (DNBC)(26) during
December 1998 to November 1999(20). Women were selected
from the DNBC on the basis of their place of residence (the greater
Copenhagen area) and their self-reported n-3 LCPUFA intake from
fish. Women with an intake of n-3 LCPUFA from fish below the
population median (<0·40g/d of n-3 LCPUFA, consuming on
average 12·3 (SD 8·2) g/d of fish) were randomly allocated to two
groups – FO and olive oil (OO). Those with an intake above the
75th percentile (>0·82g/d of n-3 LCPUFA, consuming on average
55 (SD 27) g/d of fish) were recruited to a high-fish (HF) reference
group (see trial flow in Fig. 1).
Randomisation was performed within 9 (SD 3) d after delivery,
and the mothers received supplements during the first 4 months
of lactation. The oil supplements were given in muesli bars
containing de-odourised microencapsulated oil powder, which
contained 4·5 g/d of FO and supplied 1·5 g/d n-3 LCPUFA (0·6 g
EPA+ 0·8 g DHA) or 4·5 g/d of OO. Self-reported compliance,
expressed as the percentage of muesli bars consumed relative
to the intended dose, was on average 88% in both groups(20).
A total of 107 mothers (87%) reported to have exclusively
breast-fed their infants during all 4 months of intervention,
which is common in Denmark. Women who had not exclu-
sively breast-fed their child during the 4-month intervention
period were not excluded from the trial, but the degree of
breast-feeding (in percentage of the child’s energy intake) was
estimated from the amount of formula and complementary
food ingested as described in the study by Lauritzen et al.(20).
Compliance was furthermore confirmed by GC fatty acid
analysis of maternal erythrocytes and breast milk before the
intervention (at 36·4 (SD 1·5) weeks of gestation and 9 (SD 3) d
after birth, respectively) and during the intervention (at 2 and
4 months for breast milk and at 4 months for maternal
erythrocytes). Infant erythrocyte fatty acid composition was also
determined at the end of the intervention (4 month)(20).
Investigators and families were blinded to the randomisation
during the trial, but the code was broken for all parties after the
youngest child’s first birthday (January 2001).
Infant growth was assessed twice during the supplementation
period, at age 2 and 4 months. Birth data on length and height
were collected from hospital journals. The infant’s head
circumference was measured at the first visit after randomisation –
that is, 9 (SD 3) d after delivery. Anthropometric measurements
were performed at the follow-up examinations at age 9 months,
2·5 years and 7 years, as previously described(10,20,25). Background
information regarding parental education, health, anthropometry,
etc. was collected via questionnaires(20). Data on maternal
education were collected by Official Danish Classification of
Educations from 1994 in eight categories from 1=primary school
to 8=PhD. As there were very few subjects in the extreme
categories, the education variable was re-coded to four categories
representing a high school education or less, 13–14 years of
education, 15–16 years and >17 years of education (equivalent to a
University master degree).
13-Year follow-up examination
The 140 mothers, who had not actively withdrawn their
participation from the study, were invited to participate in the
present follow-up study with their children. In total, 100 children
participated in the present 13-year follow-up study. Among the
forty mothers who did not participate, twenty mothers did not
respond to a postal letter or telephone calls, eight no longer resided
in the greater Copenhagen area, eleven did not wish to participate
because of personal reasons and one child had passed away.
Blood sample collection had not been ethically approved at the
initiation of the follow-up study, and was thus only performed in
forty-nine the children.
The follow-up examination took place either at Department of
Nutrition, Exercise and Sports, University of Copenhagen, or at
home of the family; two investigators, who were blinded
to the group allocation, performed the measurements on all
children. Height was measured twice to the nearest 0·1 cm using a
portable stadiometer (Leicester Height Measure; Child Growth
Foundation). Head, waist and hip circumferences were assessed
in triplicate with a non-stretchable measuring tape to the nearest
mm. Triceps and subscapular skinfold thicknesses were assessed
in triplicate using a Harpenden skinfold caliper with a resolution
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of 0·1mm (CMS Weighing Equipment; Baty International). The
lack of inter-investigator differences was verified in the triceps
skinfold assessments by comparison in ten subjects (P= 0·598).
Body weight (to the nearest g) and fat percentage were assessed
twice by bioimpedance on a body fat monitor scale (Omron
BF511; Mediq A/S). The assessed body fat percentage correlated
with that calculated from the sum of triceps and subscapular
skinfolds on the basis of the methods of Slaughter et al.(27)
(r 0·831, P< 0·001, n 99). For all anthropometric measures,
we used the mean of the duplicates or triplicates. Fat mass index
was calculated on the basis of the bioimpedance assessment as
follows: body fat%×body mass (kg)/height2 (m2).
Blood pressure was measured in triplicate with an automated
device (Boso-medicus Prestige unit; Bosch Sohn). The child
was asked to rest for 10min in the supine position before
the measurements, which were taken with an interval of
approximately 2min. Blood pressure was measured on the
non-dominant arm with a cuff designed for small (12–22 cm) or
medium (22–26 cm) arm circumferences, whichever fitted the
child. From these assessments, we calculated the mean of the
second and third measurement of systolic blood pressure (SBP)
and DBP. MAP was calculated as DBP+1/3× (SDP−DBP).
Pubertal status was self-assessed using Tanner Scales(28). The
Tanner Scales consist of line drawings that portray different stages
of pubertal development rated on a five-point scale (I, II, III, IV, V),
where stage I is classified as pre-pubertal and stage V as fully
matured. The boys were asked to identify their development
on the basis of their genital development and pubic hair growth,
whereas the girls were asked to identify their development
on the basis of breast development. The girls were furthermore
asked to record whether their menarche had occurred and the date
of its first occurrence.
Fingertip-prick blood samples were collected from 49% of the
children who completed the 13-year follow-up and analysed for
fatty acid composition by GC. The blood samples were collected
on chromatography paper (Whatman Ltd) prepared with 50 µg
of 2,6-di-tert-butyl-4-methylphenol (butylated hydroxytoluene;
Sigma-Aldrich), allowed to air dry and were stored at 4°C(29) until
they were shipped to the Department of Kinesiology at University
of Waterloo, Canada. The samples were stored at −80°C until
analysis using a high-throughput GC method(29). In brief, fatty
acid methyl esters were prepared from the whole-blood samples
using direct transesterification with the addition of 1ml of 14%
BF3 in methanol, 300µl of hexane and 3 µg of an internal standard
(22 : 3n-3 methyl ester; Nu-Check Prep) followed by heating at
95°C for 1 h on a heating block. The fatty acid methyl esters in
hexane were then collected and analysed on a Varian 3900 GC
equipped with a DB-FFAP 15m× 0·10mm i.d.× 0·10-µm film
thickness, nitro-terephthalic acid-modified, polyethylene glycol
capillary column (J & W Scientific from Agilent Technologies)
with hydrogen as the carrier gas with settings as described in
detail elsewhere(29). More than 90% of the fatty acid peaks in the
chromatograms were identified, and individual fatty acids are
presented as weight percentage of total fatty acids (FA%).
By the end of the 13-year examination period, the mother and
child received oral and written instructions on using a validated
web-based FFQ dietary assessment tool(30) to record the
child’s dietary intake during the last month. This tool has
been developed specifically for adolescents, and asks about
145 commonly eaten foods, dishes and drinks consumed by
Danish adolescents for breakfast, lunch and dinner, respectively.
Frequency scales were used depending on the food item.
Calculations of intake in g/d were computed on the basis of
standard portion sizes and frequencies ranging from ‘did not
drink/consume the last month’ to ‘two to four times or more
per day’ and were computed into times. The average daily energy
intake and distribution of macronutrients (in g/d and percentage
of the total energy intake) were calculated from the FFQ using
FoodCalc version 1.3 combined with the Danish Food Table.
Physical activity was assessed using a tri-axis accelerometer
(ActiGraph™ GT3X+; ActiGraph Corp.). The children were
instructed to wear the device tightly at the right hip in an elastic
belt for 7 consecutive days, and to remove it during night-time
sleep, showering and swimming. Data were re-integrated to 60-s
epochs and analysed using ActiLife (version 6; ActiGraph). Non-
wear time was defined as 20min of consecutive zeros using
vector magnitude of the three axes. Valid physical activity
recordings were defined as consecutive wear time periods of
≥1h duration and a total wear time of ≥10h/d for ≥3d.
Accordingly, eighty-eight children had valid physical activity
recordings with a mean duration of 6·7 (SD 1·7)d. Only four
children did not remove the accelerometer on one or more
nights; in these cases, sleep was removed, on the basis of visual
inspection of the individual actograms, as the difference between
time when activity stopped in the evening and time when activity
resumed in the morning. Total physical activity (counts per min)
was expressed as a vector magnitude of the total tri-axial counts
from monitor wear time divided by monitor wear time.
Statistics
Numbers in the text are means unless otherwise stated. Parental
and infant characteristics of participating and non-participating
children were compared using the unpaired t test (continuous
variables) and the χ2 test (categorical variables). Anthropometry,
body composition and growth as well as macronutrient intake,
fatty acid composition of whole blood and total physical activity
in the two randomised groups (FO and OO) were compared in
ANCOVA including age and sex as fixed effects. All models were
initially tested for sex× group interaction, and if the P value of
the interaction was <0·10 the analysis was performed separately
for boys and girls. Additional analyses were performed
after adjusting for potential confounders: maternal education
and mean parental height that tended to differ between the
randomised groups and potential mediators: puberty in
the models of all the anthropometric measures and height in the
models of body weight, body composition and blood pressure.
The non-randomised HF reference group was not included in the
ANCOVA models, but is shown in the tables for comparison.
Potential differences in categorical variables (such as pubertal
stage) between the two randomised groups were tested using
logistic regression analysis adjusted for age and sex; the
menarcheal status of the girls in the two groups was compared
using the χ2 test.
When outcome variables differed significantly between the
FO and OO group in ANCOVA, dose–response analyses were
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performed by regression analysis with maternal erythrocyte
DHA in the 4th month of lactation as the independent variable
and including children both from the two randomised groups
and from the high-fish reference group. If the ANCOVA
model showed sex× group interaction, the corresponding
dose–response regression analysis was also performed
separately for each sex, and the dose–response models
included the same confounders and mediators as the fully
adjusted ANCOVA models. In addition, the dose–response
models were adjusted for the degree of breast-feeding, as
breast-feeding would be a prerequisite for an effect of maternal
n-3 LCPUFA status on the child. Data analysis was performed
using STATA/IC version 12.1 for Mac (64-bit Intel) and SPSS
version 22, and P< 0·05 was considered statistically significant.
A post hoc power calculation showed that with a mean of
thirty-two subjects in each of the two randomised groups,
this study was powered (α= 0·05 and β= 0·80) to show an
unadjusted difference of about 0·7× SD.
Results
Children’s characteristics
Fig. 1 gives an overview of the study flow with recruitment,
randomisation, drop out and attrition in the present follow-up
study. In total, 100 children (70% of the invited children)
participated in the 13-year follow-up (Table 1), including
sixty-four from the two randomised groups (58 and 70% from the
FO and OO group, respectively). Participation rate did not differ
between the two randomised groups (P= 0·223), but there was a
skewed sex distribution in the FO group, which reflects a skew in
the original randomisation. With respect to the characteristics as
listed in Table 1, the 100 children who participated in the 13-year
follow-up did not differ from those not participating, except
for a longer duration of breast-feeding in the mothers of the
participating children (9·2 (SD 4·3) v. 7·4 (SD 4·5) months,
P= 0·049). The forty-nine children who provided blood spot
samples for fatty acid analysis were slightly older (13·7 (SD 0·4) v.
13·3 (SD 0·3) years, P< 0·001) than those who were not
blood sampled, but this did not differ with respect to dietary
macronutrient contribution, maternal education or sex distribution
(data not shown).
The two randomised groups did not differ with respect to the
children’s energy intake, dietary macronutrient distribution or
total physical activity, and no sex× group interactions were
observed for any of these variables (online Supplementary
Table S1). Moreover, no differences were observed in the
content of the major fatty acids in whole blood at 13 years of
age (online Supplementary Table S2).
Growth and pubertal stage
The children from the FO group were 3·7 (95% CI 0·3, 7·1) cm
shorter than those from the SO group at 13 years of age
(Table 2). This difference did not change by adjustment for
mean parental height (Table 2). However, there was a tendency
for lower puberty scores in the children of the FO compared
with the OO group at 13 years (P= 0·068, logistic regression
with adjustment for age and sex) (Fig. 2), and the difference in
height seemed to be driven by this, as the height difference
D72–13 trial profile
Pregnant women contacted by DNBC
(n 1473)
Included in HF reference group
after delivery (n 53)
Included in randomised trial


















study at 13 years (n 48)
Not withdrawn from
study at 13 years (n 49)
Not withdrawn from
study at 13 years (n 43)
Declined participation     1
Moved away from Cph    4
Passed away                   1
No contact established    6 
Declined participation   7
Moved away from Cph  3
No contact established 8
Declined participation   3
Moved away from Cph  1
No contact established  6
Fig. 1. Overview of the study flow. DNBC, Danish National Birth Cohort; HF, high-fish reference; FO, fish oil; OO, olive oil; Cph, Copenhagen.
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between the two groups was no longer significant after
adjustment for puberty (2·4 (95% CI 0·5, 5·3) cm, P= 0·101).
Overall, menarche had occurred in 66% of the girls, with no
difference between the two randomised groups (P= 0·31).
None of the other anthropometric or body composition
variables differed between the two randomised groups at
13 years of age or showed sex× group interactions (Table 2).
Dose–response analysis showed no clear negative association
between maternal erythrocyte DHA at the end of the intervention
period and height of the children at 13 years of age (all children
included and adjusted for sex, age, mean parental height and
breast-feeding: β=− 0·5 (95% CI −1·2, 0·2) cm/FA%, P= 0·17,
n 98) (online Supplementary Fig. S1).
Blood pressure
The SBP, DBP and MAP of the children at 13 years did not differ
between the randomised groups with the sexes combined, but a
significant sex× group interaction was present for both DBP and
MAP (Table 2). Analysis of FO v. OO adjusted for age and height
in boys and girls separately showed a 3·9 (95% CI 0·2, 7·5)mmHg
(P= 0·041) higher DBP and 3·6 (95% CI 0·2, 7·0)mmHg
(P= 0·040) higher MAP with FO compared with OO in the boys
and no differences in the girls. The difference in boys did not
disappear after adjustment for puberty or physical activity (MAP
difference adjusted for both: 4·9 (95% CI 1·0, 8·9)mmHg,
P= 0·017, n 27).
The sex-specific effect on MAP was supported by an inter-
action (P= 0·096) in the dose–response analysis (all children
included), and the sex-specific analysis indicated a positive
association between maternal erythrocyte DHA and MAP in
boys (β= 0·7 (95% CI −0·1, 1·5)mmHg/FA%, P= 0·088, n 53),
but not in girls (β= − 0·3 (95% CI −1·1, 0·6)mmHg/FA%,
P= 0·52, n 45) (Fig. 3). The association between maternal
erythrocyte DHA and DBP in boys was weaker (β= 0·7 (95% CI
−0·2, 1·7)mmHg/FA%, P = 0·110, n 53) than that for MAP.
Discussion
This follow-up study showed that adolescents of mothers who
were randomised to FO supplementation during lactation were
shorter than those whose mothers received OO supplements,
an association that seemed to be driven by slower pubertal
maturation. We also found a sex-specific effect of maternal FO
supplementation on DBP and MAP, driven by a higher blood
pressure in the boys from the FO group compared with the OO
group and no difference in the girls. The effect of the intervention
on blood pressure was independent of the effect on height and
to some extent supported by dose–response associations with
maternal DHA status at the end of the intervention period.
A recent Cochrane meta-analysis based on three trials
concluded that maternal FO supplementation during pregnancy
and lactation did not affect child weight and length up to 2 years
of age and beyond(31), although this was indicated in an
earlier version of this analysis based on fewer trials but more
participants(32). To our knowledge, the present study is the
first study to investigate potential effects of early n-3 LCPUFA
supplementation on growth during puberty, a time period with
very high growth rates and major changes in body composition.
The observation of shorter stature of children in the FO group at
13 years of age in the present study is in line with a previously
observed negative association between erythrocyte DHA con-
centration of FO-supplemented mothers in the third trimester of
pregnancy and child height at 6 years of age(33). In contrast,
others have found increased length at 6 years of age in a trial with
LCPUFA-enriched infant formula(34). Interestingly, a recent,
genome-wide association analysis showed associations between
certain SNP in the genes encoding for the fatty acid desaturases
Table 1. Characteristics of the children in the three groups
(Mean values and standard deviations or frequency (n))
HF OO FO
At baseline Mean SD Mean SD Mean SD
n (M:F) 18:18 16:17 19:12
Paternal height (m) 1·81 0·15 1·80 0·07 1·81 0·05
Maternal height (m) 1·71 0·07 1·70 0·05 1·66 0·05
Maternal education (%)
<10–12 years (high school or less) 33·3 12 30·3 10 25·8 8
13–14 years 19·4 7 30·3 10 9·7 3
15–16 years 22·2 8 21·2 7 45·2 14
>17 years (higher academic) 25·0 9 18·2 6 19·4 6
Maternal age at delivery (years) 32·2 3·9 30·5 3·8 30·9 3·9
Parity (% primiparous) 38·9 48·5 43·3
Gestational length (weeks) 40·1 1·2 40·1 1·2 40·3 1·0
Birth weight (kg) 3·58 0·47 3·54 0·45 3·64 0·45
Birth length (cm) 52·4 1·9 52·2 2·1 52·6 2·3
After randomisation
Breast-feeding duration (months) 9·6 4·1 9·6 4·6 8·4 4·1
Breast milk DHA at 4 months (FA%) 0·73 0·35 0·41 0·21 1·29 0·41
Infant erythrocyte DHA at 4 months (FA%) 6·9 2·2 5·8 2·0 7·9 3·1
Child age at follow-up (years) 13·5 0·4 13·4 0·4 13·5 0·4
HF, high-fish reference; OO, olive oil; FO, fish oil; M, male; F, female; FA%, weight percentage of total fatty acids.
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Table 2. Anthropometrics and blood pressure at 13 years of age in children of the three groups*
(The raw data are given as mean values and standard deviations with n in parenthesis if different from column n. The results from the statistical comparisons of the two randomised groups (olive oil (OO)
and fish oil (FO)) performed by ANCOVA with inclusion of a sex × group interaction term are given as mean differences with their standard errors and P values)
HF OO FO
Boys Girls Boys Girls Boys Girls FO v. OO (sex and age adjusted) FO v. OO (with additional adjustments)†
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD Pgroup × sex Mean SE P Mean SE P
n 18 18 16 17 19 12
Height (m) 1·64 0·10 1·64 0·07 1·63 0·08 1·64 0·06 1·60 0·06 1·59 0·08 (11) 0·658 − 3·7 1·6 0·032 −3·4 1·6 0·035
Weight (kg) 47·0 9·5 49·9 9·5 48·7 7·2 48·2 9·1 48·5 7·8 48·0 11·4 0·997 −0·6 2·1 0·779 −0·9 2·0 0·664
BMI (kg/m2) 17·5 2·8 18·4 3·3 18·3 2·0 18·0 3·3 18·8 2·2 18·7 3·4 0·879 0·5 0·7 0·460 0·9 0·7 0·215
Fat mass index‡ 1·97 1·26 3·63 2·02 2·43 1·19 3·61 1·71 2·81 1·26 3·94 2·53 0·960 0·3 0·4 0·423 0·5 0·4 0·258
Body fat%‡ 10·7 5·9 18·9 6·4 12·9 5·2 19·2 7·0 14·6 5·0 19·7 8·8 0·716 1·1 1·6 0·496 1·6 1·7 0·356
Sum of skinfolds (mm) 8·1 2·2 11·4 4·8 8·7 2·7 11·7 2·8 9·1 3·0 11·6 5·0 0·822 0·1 0·9 0·917 0·3 0·9 0·753
Waist circumference (cm) 68·7 8·0 71·7 7·2 71·2 4·5 69·9 5·9 69·8 5·9 69·6 10·7 0·767 −1·2 1·7 0·492 −0·6 1·7 0·726
DBP (mmHg) 61 8 63 5 61 6 65 5 64 4 63 5 0·022 Boys: 3·6 (SE 1·7) 0·048 3·9 1·8 0·041
Girls:−2·3 (SE 1·9) 0·226 −2·1 2·0 0·298
SBP (mmHg) 107 8 105 5 109 10 108 6 110 6 104 9 0·223 −1·4 1·9 0·467 −0·6 1·7 0·742
MAP (mmHg) 76·6 6·6 76·8 4·4 76·8 6·4 79·5 3·8 79·5 3·4 76·6 5·7 0·030 Boys: 2·6 (SE 1·7) 0·137 3·6 1·7 0·040
Girls: −2·9 (SE 1·8) 0·126 −2·3 1·9 0·248
HF, high fish; DBP, diastolic blood pressure; SBP, systolic blood pressure; MAP, mean arterial pressure.
* Data for the high fish group are included as reference.
† The model for height was adjusted for sex, age and mean parental height; models for body weight and body composition outcomes were adjusted for sex, age and puberty; and the blood pressure models were adjusted for sex, age
and height.
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with the control group, but this difference in BMI was also no
longer evident at 6 years. In line with this, a recent systematic
review states that the results regarding early supply of n-3
LCPUFA and later adiposity in children are inconsistent(2).
In adolescence, height is pronouncedly affected by pubertal
stage, and the effect on height at 13 years was no longer
significant after adjustment for puberty, indicating that the
difference in height may be due to a slower pubertal maturation
with early FO supplementation. A tendency towards later onset
of puberty after maternal FO supplementation was indicated,
although not statistically significant, and the study may be
underpowered to truly detect such self-reported developmental
differences. A delay in puberty could be due to a different
growth pattern, as BMI decreased from 2·5 to 7 years of age in
the FO group, whereas it increased in the OO group, and it
could be speculated that this could reflect a later adiposity
rebound in the FO group. In a Danish cohort study, a delay in
adiposity rebound was observed in children of mothers with a
breast milk DHA content in the upper quintile compared with
the other quintiles(14). No sex-specific effects on growth or body
composition were seen in our previous FO trial in infants(36),
which, however, showed increased serum insulin-like growth
factor (IGF)-1 concentrations after FO supplementation in
boys only(37). In a FO trial in adolescent boys, we also
found a positive association between changes in erythrocyte
n-3 LCPUFA and changes in plasma IGF-1 during the
intervention(38). To our knowledge, long-term sex-specific
effects of early n-3 LCPUFA supplementation on growth or
body composition have not been investigated previously, but
our data in the present follow-up study do not indicate any
interaction between n-3 LCPUFA supplementation and sex on
the anthropometric outcomes.
The observed higher blood pressures in 13-year-old boys, but
not in girls, exposed to breast milk from FO-supplemented v.
OO-supplemented mothers during infancy confirm the pre-
viously observed effect at 7 years in this study population and
may indicate that early n-3 LCPUFA intake can have effects that
persist into puberty. The observed results are in line with our
previous findings in cross-sectional studies of 8–11-year-old
Danish children, which showed positive associations between
whole-blood n-3 LCPUFA and blood pressure in boys
only(22,23). The studies are, however, in contrast with previous
observations from randomised trials in adults, which generally
show the blood pressure-reducing effects of n-3 LCPUFA(39).
Furthermore, Forsyth et al.(17) have demonstrated that infants
fed formula enriched with n-3 LCPUFA had lower blood pres-
sure at age 6 years compared with children receiving formula
with no n-3 LCPUFA and a low α-linolenic acid content, a
finding that is supported by animal studies(15,16). In line with
this, a recent observational study showed that children who
received breast milk with a high content of n-3 LCPUFA had
lower blood pressure at 12 years of age compared with children
who were never breast-fed(40). The lower height in the FO
group in the present study could not explain the increased
blood pressure, as the effect was found regardless of adjustment
for height, and furthermore blood pressure is generally posi-
tively associated with height in children(41).
Previous studies that have investigated potential sex-specific
effects of FO supplementation in randomised trials seem to
indicate that FO supplementation dampens sex differences –
particularly in relation to blood pressure(42) – but also
cognitive outcomes(43). Moreover, sex has been shown to be an
important determinant of LCPUFA status in both rats and
humans(38). This is likely mediated by the influence of sex
hormones on the enzymatic synthesis of LCPUFA, resulting in a
higher content of DHA in, for example, the liver and plasma
in females compared with males(44,45). In contrast, data from
the present study did not show sex differences in DHA status
at 13 years, but fatty acid analyses were also only performed
in a subgroup of the children. It is unknown whether n-3
LCPUFA intake can affect sex hormone levels, but this
may hypothetically explain why the children of the
FO-supplemented mothers tended to have delayed pubertal
maturation than the children of the OO-supplemented mothers.
More studies are needed to elucidate this further.
The difference in puberty could be a chance finding, as one
major limitation of the present study is the relatively low sample
size. Insufficient statistical power could particularly be an issue in
the sex-specific analyses. However, to our knowledge, this is the
only study that followed-up children from a randomised con-
trolled trial with early n-3 LCPUFA supplementation at the age of
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Fig. 3. Association between mean arterial blood pressure at 13 years of age
adjusted for age, height and breast-feeding and maternal erythrocyte DHA
(erythrocyte DHA) at the end of the intervention period in girls and boys in the
three groups ( , maternal fish oil-supplemented group; , olive oil control
group; , maternal high fish intake reference group). The regression lines are
given with 95% prediction interval. FA%, weight percentage of total fatty acids.
Girls R 2 linear = 0·009; boys R 2 linear = 0·057.
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compared with what could be anticipated in such a long-term
study, and the participating children were reasonably repre-
sentative of the initial trial population. However, owing to the
selective nature of the recruiting procedure for the original trial,
the children were generally not representative for the overall
Danish population, but this is expected in this type of trial.
Puberty was self-assessed by the children in order to respect
their sexual privacy. Although the line drawings used to support
the children’s puberty ratings have been validated previously(46),
this may have given rise to some imprecision. The study could
have been strengthened by the measurement of serum IGF-1 to
support the growth measurements, but venous blood sampling
was unfortunately not possible, and we were only able to get
fingertip prick blood samples from half of the children, as ethics
approval for this procedure was delayed. We did not manage to
get blood from all the infants at the end of the intervention, and
we have therefore used maternal erythrocyte DHA in the dose–
response analyses adjusted for the degree of breast-feeding. We
have also data on breast milk fatty acid composition, but this
fluctuates from day to day, and thus would not provide a stable
measure of the infants DHA intake during the intervention. In
this study, we performed a number of statistical tests, but we did
not apply, for example, Bonferroni correction, first of all because
the study is exploratory in its nature, and also because many of
the outcomes were associated, and a Bonferroni correction
would be overly conservative.
The potential delay in children’s sexual maturation and thereby a
reduction in height at 13 years indicated in this study could have
long-term effects on final height. However, some studies indicate
that delayed puberty is associated with an increase in adult height
caused by a longer period of pre-pubertal growth(47). Furthermore,
fish intake is high and FO supplementation in infancy is common
in Nordic countries, especially in Norway, and the populations in
these countries are among the tallest in the world(48). However, the
higher blood pressure among boys from the maternal FO group is
consistent with results from the 7-year follow-up. It may be an
adverse effect if it tracks into adulthood, as increased blood
pressure is one of the major determinants of CVD and stroke. The
children are as mentioned not representative of the Danish
population, but if confirmed the findings may reflect biological
effects, and thus may be transferable to children in general. It is
therefore crucial to perform long-term follow-up studies on other
early n-3 LCPUFA supplementation trials, and ideally these studies
should also explore the potential for sex specificity.
In conclusion, the results of this study showed that early
n-3 LCPUFA intake was associated with lower height in early
adolescence and with increased DBP in boys only. However,
due to the small sample size of the study, these novel findings
need to be confirmed in larger randomised controlled trials.
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